Kooperativer Bibliotheksverbund

Berlin Brandenburg

and
and

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Language
Year
  • 1
    Language: English
    In: Cancer Research, 04/15/2011, Vol.71(8 Supplement), pp.3862-3862
    ISSN: 0008-5472
    E-ISSN: 1538-7445
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Language: English
    In: Cancer Research, 04/15/2011, Vol.71(8 Supplement), pp.3951-3951
    ISSN: 0008-5472
    E-ISSN: 1538-7445
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Language: English
    In: Cancer Research, 04/15/2011, Vol.71(8 Supplement), pp.3961-3961
    ISSN: 0008-5472
    E-ISSN: 1538-7445
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Language: English
    In: Cancer Research, 04/15/2012, Vol.72(8 Supplement), pp.5035-5035
    ISSN: 0008-5472
    E-ISSN: 1538-7445
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Language: English
    In: Cancer Research, 04/15/2012, Vol.72(8 Supplement), pp.1164-1164
    ISSN: 0008-5472
    E-ISSN: 1538-7445
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Language: English
    In: Cancer Research, 04/15/2012, Vol.72(8 Supplement), pp.3151-3151
    ISSN: 0008-5472
    E-ISSN: 1538-7445
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Language: English
    In: Cancer Research, 04/15/2012, Vol.72(8 Supplement), pp.3654-3654
    ISSN: 0008-5472
    E-ISSN: 1538-7445
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    In: International Journal of Cancer, September 2015, Vol.137(6), pp.1406-1416
    Description: This study aimed to assess the applicability of in combination with the soluble urokinase plasminogen activator receptor (suPAR) protein as a diagnostic and/or prognostic biomarker for prostate cancer (PCa) patients. levels by qRT‐PCR and suPAR levels by ELISA were evaluated in serum samples from 146 PCa patients, 35 benign prostate hyperplasia (BPH) patients and 18 healthy controls. Antigen levels of suPAR differed between healthy controls and PCa or BPH patients, whereas levels differed between PCa and BPH patients or healthy controls (  7, with higher levels in the latter group ( = 0.011), and levels were higher in the tumor stage group T3‐T4 compared with the T1‐T2 group ( = 0.039). A high concentration of suPAR was associated with a poor disease‐specific survival (DSS;  = 0.039). The combination of suPAR and levels identified a patient group possessing high levels for both parameters. This was associated with a poorer 10‐year overall survival (OS) and DSS, with a 6.38‐fold increased risk of death and a 7.68‐fold increased risk of tumor‐related death ( = 0.00026 and  = 0.014; univariate Cox's regression analysis). In a multivariate Cox's regression analysis PCa patients with high levels of suPAR and showed a 5.72‐fold increased risk of death in OS ( = 0.006). In summary, the differences between the PCa/BPH/healthy control cohorts for either suPAR and levels in conjunction with the association of combined high suPAR/ levels with a poor prognosis suggest a diagnostic and prognostic impact for PCa patients. What's new? Prostate cancer (PCa) sheds cells, genetic fragments, and proteins into the bloodstream that can be used as quantitative biomarkers for diagnosis, staging, prognostication, and monitoring. This study suggests that serum levels of soluble urokinase plasminogen activator receptor (suPAR) and are both useful as diagnostic biomarkers. High serum level of suPAR is also significantly associated with poor disease‐specific survival, and the combination of /suPAR levels is significantly correlated with 10‐year overall and disease‐specific survival in patients. suPAR and the combination of suPAR with may thus have a prognostic impact, indicating the potential value of combining protein and miRNA biomarkers.
    Keywords: Mir‐375 ; Urokinase Plasminogen Activator Receptor ; Prostate Cancer ; Diagnosis ; Overall Survival ; Disease‐Specific Survival
    ISSN: 0020-7136
    E-ISSN: 1097-0215
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Language: English
    In: PLoS ONE, 01 January 2015, Vol.10(6), p.e0128235
    Description: Although an increased level of the prostate-specific antigen can be an indication for prostate cancer, other reasons often lead to a high rate of false positive results. Therefore, an additional serological screening of autoantibodies in patients' sera could improve the detection of prostate cancer. We performed protein macroarray screening with sera from 49 prostate cancer patients, 70 patients with benign prostatic hyperplasia and 28 healthy controls and compared the autoimmune response in those groups. We were able to distinguish prostate cancer patients from normal controls with an accuracy of 83.2%, patients with benign prostatic hyperplasia from normal controls with an accuracy of 86.0% and prostate cancer patients from patients with benign prostatic hyperplasia with an accuracy of 70.3%. Combining seroreactivity pattern with a PSA level of higher than 4.0 ng/ml this classification could be improved to an accuracy of 84.1%. For selected proteins we were able to confirm the differential expression by using luminex on 84 samples. We provide a minimally invasive serological method to reduce false positive results in detection of prostate cancer and according to PSA screening to distinguish men with prostate cancer from men with benign prostatic hyperplasia.
    Keywords: Sciences (General)
    E-ISSN: 1932-6203
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    In: International Journal of Cancer, 01 November 2014, Vol.135(9), pp.2096-2106
    Description: Chemokines are involved in both the negative and positive regulation of inflammatory processes, angiogenesis and cancer/cancer stem cell proliferation as well as the chemoattraction of tumor cells to metastatic sites. The aim of this study was to measure the mRNA expression levels of three chemokines, , and , in soft tissue sarcomas (STSs) and to assess the correlations between these levels as well as their correlations with clinicopathological data and the disease‐specific survival of STS patients. The mRNA levels of , and were analyzed in tumor tissues from 126 STS patients using qPCR. Low mRNA expression of and was significantly correlated with a worse prognosis (RR = 1.98;  = 0.019 and RR = 2.10;  = 0.014; multivariate Cox's regression analysis). A combined low expression of and was associated with a significantly increased risk of tumor‐related death as compared to patients with high expression levels of both chemokines (RR = 3.08;  = 0.003). A gender‐specific multivariate analysis revealed that female STS patients with low mRNA expression had a 3.46‐fold increased risk of death ( = 0.004). Low expression of both and mRNAs resulted in an additive 5.37‐fold increased risk of tumor‐related death ( = 0.003) as compared to those with high expression of both parameters in female patients. In conclusion, this is the first study to show a significant correlation between combined low expression of and and a poor prognosis for STS patients, particularly in female patients. What's New? While chemokines are known to play key roles in both driving and preventing cancer progression, their expression and biological significance in soft tissue sarcoma (STS) remain unclear. This study shows that monocyte chemotactic protein‐1 (MCP1/CCL2) and fractalkine (CX3CL1) affect the prognosis of STS patients. The high mRNA expression of both chemokines is correlated with a good outcome in STS patients, particularly in female STS patients. The study provides evidence supporting the hypothesis that CCL2 and CX3CL1 have a promoting effect on apoptosis induction in STS. A possible explanation for the gender difference is the gender‐specific regulation of chemokines by hormones/receptors.
    Keywords: Chemokine ; Ccl2 ; Ccl7 ; Cx3cl1 ; Soft Tissue Sarcoma
    ISSN: 0020-7136
    E-ISSN: 1097-0215
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages